Maria Gantzel
Maria Gantzel has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Christian Sylvest Meyhoff
Department of Anaesthesia and Intensive Care Copenhagen University Hospital ‐ Bispebjerg and Frederiksberg Copenhagen Denmark
1 shared publicationDaniel Hägi‐Pedersen
Research Centre of Anaesthesiology and Intensive Care Medicine, Department of Anaesthesiology, Næstved‐Slagelse‐ Ringsted Hospitals Denmark
1 shared publicationEllen C.L. Løkkegaard
Department of Gynecology and Obstetrics, Copenhagen University Hospital - North Zealand, Hillerod, Denmark; Department of Clinical Research, Copenhagen University Hospital - North Zealand, Hillerod, Denmark
1 shared publicationHelle Timm
UCSF - Center for Health Research, Copenhagen University Hospital, Copenhagen, Denmark; National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark; Centre for Health Sciences, University of the Faroe Islands, Tórshavn Faroe Islands
1 shared publicationJane M. Bendix
Department of Gynecology and Obstetrics, Copenhagen University Hospital - North Zealand, Hillerod, Denmark; Department of Clinical Research, Copenhagen University Hospital - North Zealand, Hillerod, Denmark
1 shared publicationJanus Christian Jakobsen
Department of Regional Health Research, The Faculty of Health Sciences University of Southern Denmark
1 shared publication
Latest Publications
- Open Access
- 4 August 2022
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 66 (9) , 1070-1076
Effect of dexamethasone on intraoperative remifentanil dose in total knee arthroplasty surgery under general anaesthesia
Background: The effects of glucocorticoids may include both genomic and rapid nongenomic effects. The potential rapid analgesic effect during surgery has not previously been investigated. We aimed to explore the effect of dexamethasone on intraoperative infusion rate of remifentanil in patients undergoing total knee arthroplasty (TKA) surgery under general anaesthesia. Methods: In this post hoc subgroup analysis, we included patients randomised in the DEX-2-TKA trial, who were operated under total intravenous anaesthesia with remifentanil and propofol. Trial medication, intravenous dexamethasone 24 mg or placebo, was administered immediately after anaesthesia onset. The primary outcome was the median weight-corrected infusion rate of remifentanil during surgery. Secondary outcomes included median weight-corrected infusion rate of propofol, median intraoperative bispectral index and time spent in the post-anaesthesia care unit. Results: Eighty-seven patients were included in the analysis of the primary outcome. A significantly higher remifentanil infusion rate was observed in the dexamethasone group compared with the placebo group, p = .02. None of the secondary outcomes resulted in statistically significant differences between groups. Conclusion: This explorative post hoc analysis of the randomised DEX-2-TKA trail showed that patients undergoing TKA surgery under general anaesthesia and who received dexamethasone seemed to have a higher remifentanil infusion rate compared with patients who received placebo. The clinical implications of the potentially increased remifentanil infusion rate need to be validated and explored further.
- 4 August 2022
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 66 (9) , 1070-1076
Open AccessEffect of dexamethasone on intraoperative remifentanil dose in total knee arthroplasty surgery under general anaesthesia
Background: The effects of glucocorticoids may include both genomic and rapid nongenomic effects. The potential rapid analgesic effect during surgery has not previously been investigated. We aimed to explore the effect of dexamethasone on intraoperative infusion rate of remifentanil in patients undergoing total knee arthroplasty (TKA) surgery under general anaesthesia. Methods: In this post hoc subgroup analysis, we included patients randomised in the DEX-2-TKA trial, who were operated under total intravenous anaesthesia with remifentanil and propofol. Trial medication, intravenous dexamethasone 24 mg or placebo, was administered immediately after anaesthesia onset. The primary outcome was the median weight-corrected infusion rate of remifentanil during surgery. Secondary outcomes included median weight-corrected infusion rate of propofol, median intraoperative bispectral index and time spent in the post-anaesthesia care unit. Results: Eighty-seven patients were included in the analysis of the primary outcome. A significantly higher remifentanil infusion rate was observed in the dexamethasone group compared with the placebo group, p = .02. None of the secondary outcomes resulted in statistically significant differences between groups. Conclusion: This explorative post hoc analysis of the randomised DEX-2-TKA trail showed that patients undergoing TKA surgery under general anaesthesia and who received dexamethasone seemed to have a higher remifentanil infusion rate compared with patients who received placebo. The clinical implications of the potentially increased remifentanil infusion rate need to be validated and explored further.